As part of our series focussing on medicines available in Australia, this review summarises the results of cemiplimab from the EMPOWER-Lung 1 and EMPOWER-Lung 3 trials as well as the 5-year follow-up data from EMPOWER-Lung 1 in patients with squamous or non-squamous histology, and the results of an exploratory subgroup analysis in patients with brain metastases.
Guiding commentary has been provided by Professor Nick Pavlakis, a medical oncologist with more than 20 years’ experience in clinical and translational research.
Please login below to download this issue (PDF)